{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:01:02Z","timestamp":1790892062555,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11095-026-04056-w","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:32:07Z","timestamp":1772065927000},"page":"1821-1834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lapatinib-Loaded Glucose-Functionalized Silver Nanoparticles Enhance Efficacy in HER2-Positive Breast Cancer Cells and Modulate Survival-Associated Genes"],"prefix":"10.1007","volume":"43","author":[{"given":"Behnaz","family":"Dolatabadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Peymani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Rouhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Salehzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0391-1769","authenticated-orcid":false,"given":"Ali","family":"Zarrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"4056_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03378-0","author":"Z Guo","year":"2025","unstructured":"Guo Z, Dong RW, Wu Y, Dong S, Alahari SK. Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment. Oncogene. 2025. https:\/\/doi.org\/10.1038\/s41388-025-03378-0.","journal-title":"Oncogene"},{"key":"4056_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s43032-024-01666-w","author":"P Pourmasoumi","year":"2024","unstructured":"Pourmasoumi P, Moradi A, Bayat M. BRCA1\/2 mutations and breast\/Ovarian cancer risk: a new insights review. Reprod Sci. 2024. https:\/\/doi.org\/10.1007\/s43032-024-01666-w.","journal-title":"Reprod Sci"},{"issue":"3","key":"4056_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036905","volume":"103","author":"EI Obeagu","year":"2024","unstructured":"Obeagu EI, Obeagu GU. Breast cancer: a review of risk factors and diagnosis. Medicine (Baltimore). 2024;103(3):e36905.","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"4056_CR4","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1158\/1535-7163.MCT-20-0385","volume":"19","author":"S Dees","year":"2020","unstructured":"Dees S, Ganesan R, Singh S, Grewal IS. Emerging CAR-T cell therapy for the treatment of triple-negative breast cancer. Mol Cancer Ther. 2020;19(12):2409\u201321.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"4056_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071987","volume":"15","author":"MF Mercogliano","year":"2023","unstructured":"Mercogliano MF, Bruni S, Mauro FL, Schillaci R. Emerging targeted therapies for HER2-positive breast cancer. Cancers (Basel). 2023;15(7):1987.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4056_CR6","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.clinthera.2008.08.008","volume":"30","author":"PJ Medina","year":"2008","unstructured":"Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008;30(8):1426\u201347.","journal-title":"Clin Ther"},{"issue":"4","key":"4056_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0297043","volume":"19","author":"CE Fonseca-Alves","year":"2024","unstructured":"Fonseca-Alves CE, Leis-Filho AF, Lacerda ZA, de Faria Lainetti P, Amorim RL, Rogatto SR. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: an analysis in human and canine prostate cancer cells. PLoS ONE. 2024;19(4):e0297043.","journal-title":"PLoS ONE"},{"issue":"11","key":"4056_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2013.115","volume":"45","author":"YY Lee","year":"2013","unstructured":"Lee YY, Kim H-P, Kang MJ, Cho B-K, Han S-W, Kim T-Y, et al. Phosphoproteomic analysis identifies activated MET-axis PI3K\/AKT and MAPK\/ERK in lapatinib-resistant cancer cell line. Exp Mol Med. 2013;45(11):e64-e.","journal-title":"Exp Mol Med"},{"issue":"6","key":"4056_CR9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3109\/10799893.2015.1030412","volume":"35","author":"Y Sun","year":"2015","unstructured":"Sun Y, Liu W-Z, Liu T, Feng X, Yang N, Zhou H-F. Signaling pathway of MAPK\/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res. 2015;35(6):600\u20134.","journal-title":"J Recept Signal Transduct Res"},{"key":"4056_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.111055","author":"M Tufail","year":"2024","unstructured":"Tufail M, Wan W-D, Jiang C, Li N. Targeting PI3K\/Akt\/mTOR signaling to overcome drug resistance in cancer. Chem Biol Interact. 2024. https:\/\/doi.org\/10.1016\/j.cbi.2024.111055.","journal-title":"Chem Biol Interact"},{"issue":"2","key":"4056_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5414\/CP203123","volume":"56","author":"R Madden","year":"2018","unstructured":"Madden R, Kosari S, Peterson GM, Bagheri N, Jackson T. Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: a systematic review. Int J Clin Pharmacol Ther. 2018;56(2):72.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"4056_CR12","volume":"5","author":"AS Zimmer","year":"2022","unstructured":"Zimmer AS, Van Swearingen AE, Anders CK. HER2\u2010positive breast cancer brain metastasis: a new and exciting landscape. Cancer Rep (Hoboken). 2022;5(4):e1274.","journal-title":"Cancer Rep (Hoboken)"},{"key":"4056_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcp.2024.101985","volume":"78","author":"B Dolatabadi","year":"2024","unstructured":"Dolatabadi B, Peymani M, Rouhi L, Salehzadeh A, Hushmandi K, Hashemi M. The prospective role of lapatinib as an adjuvant therapy in prevalent cancers: insights from in silico analysis targeting EGFR and HER2. Mol Cell Probes. 2024;78:101985.","journal-title":"Mol Cell Probes"},{"key":"4056_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2024.124635","volume":"401","author":"R Ghadi","year":"2024","unstructured":"Ghadi R, Wadikar A, Yadav V, Kuche K, Date T, Nallamothu B, et al. Advancing apoptosis induction in triple negative breast cancer: empowering treatment with tyrosine-stapled mixed micelles of lapatinib. J Mol Liq. 2024;401:124635.","journal-title":"J Mol Liq"},{"issue":"2","key":"4056_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.2174\/0118715206327756240830062531","volume":"25","author":"Y Sun","year":"2025","unstructured":"Sun Y, Wang D, Yuan C, Lang X, Fu S. Lapatinib: a potential therapeutic agent for colon cancer targeting ferroptosis. Anti-Cancer Agents Med Chem. 2025;25(2):114\u201323.","journal-title":"Anti-Cancer Agents Med Chem"},{"key":"4056_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122899","author":"AN Al-Thani","year":"2024","unstructured":"Al-Thani AN, Jan AG, Abbas M, Geetha M, Sadasivuni KK. Nanoparticles in cancer theragnostic and drug delivery: a comprehensive review. Life Sci. 2024. https:\/\/doi.org\/10.1016\/j.lfs.2024.122899.","journal-title":"Life Sci"},{"issue":"15","key":"4056_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ma16155354","volume":"16","author":"J Baranwal","year":"2023","unstructured":"Baranwal J, Barse B, Di Petrillo A, Gatto G, Pilia L, Kumar A. Nanoparticles in cancer diagnosis and treatment. Materials. 2023;16(15):5354.","journal-title":"Materials"},{"key":"4056_CR18","doi-asserted-by":"crossref","unstructured":"Raj S, Khurana S, Choudhari R, Kesari KK, Kamal MA, Garg N, et al. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. Semin Cancer Biol. 2021;69:166\u2013177.","DOI":"10.1016\/j.semcancer.2019.11.002"},{"issue":"1","key":"4056_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-020-0817-4","volume":"3","author":"L Palanikumar","year":"2020","unstructured":"Palanikumar L, Al-Hosani S, Kalmouni M, Nguyen VP, Ali L, Pasricha R, et al. pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics. Commun Biol. 2020;3(1):95.","journal-title":"Commun Biol"},{"issue":"5","key":"4056_CR20","doi-asserted-by":"publisher","first-page":"2103444","DOI":"10.1002\/advs.202103444","volume":"9","author":"J Zhang","year":"2022","unstructured":"Zhang J, Lin Y, Lin Z, Wei Q, Qian J, Ruan R, et al. Stimuli-responsive nanoparticles for controlled drug delivery in synergistic cancer immunotherapy. Advanced Science. 2022;9(5):2103444.","journal-title":"Advanced Science"},{"issue":"1","key":"4056_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-06275-4","volume":"15","author":"MB Aboul-Nasr","year":"2025","unstructured":"Aboul-Nasr MB, Yasien AA, Mohamed SS, Aboul-Nasr YB, Obiedallah M. Exploring the anticancer potential of green silver nanoparticles\u2013paclitaxel nanocarrier on MCF-7 breast cancer cells: an in vitro approach. Sci Rep. 2025;15(1):20198.","journal-title":"Sci Rep"},{"key":"4056_CR22","doi-asserted-by":"crossref","unstructured":"Mirza Z, Karim S. Nanoparticles-based drug delivery and gene therapy for breast cancer: recent advancements and future challenges. Semin Cancer Biol. 2021;69:226\u2013237.","DOI":"10.1016\/j.semcancer.2019.10.020"},{"issue":"1","key":"4056_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.biotechadv.2008.09.002","volume":"27","author":"M Rai","year":"2009","unstructured":"Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv. 2009;27(1):76\u201383.","journal-title":"Biotechnol Adv"},{"issue":"1-2","key":"4056_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cis.2010.02.001","volume":"156","author":"KB Narayanan","year":"2010","unstructured":"Narayanan KB, Sakthivel N. Biological synthesis of metal nanoparticles by microbes. Adv Colloid Interface Sci. 2010;156(1\u20132):1\u201313.","journal-title":"Adv Colloid Interface Sci"},{"issue":"3","key":"4056_CR25","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1007\/s12668-024-01473-2","volume":"14","author":"A Gul","year":"2024","unstructured":"Gul A, Baig MN, Ahmed D, Najam Z, Aslam T, Ali S. Green synthesis of silver nanoparticles from Spirulina platensis extract: antibacterial and antioxidant potential. BioNanoScience. 2024;14(3):2327\u201336.","journal-title":"BioNanoScience"},{"issue":"4","key":"4056_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/nano11040964","volume":"11","author":"HI Gomes","year":"2021","unstructured":"Gomes HI, Martins CS, Prior JA. Silver nanoparticles as carriers of anticancer drugs for efficient target treatment of cancer cells. Nanomaterials. 2021;11(4):964.","journal-title":"Nanomaterials"},{"issue":"10","key":"4056_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.23823","volume":"38","author":"MD Rivera","year":"2024","unstructured":"Rivera MD, Vazquez\u2010Duhalt R, Castro\u2010Longoria E, Juarez\u2010Moreno K. Synergistic anticancer effects and reduced genotoxicity of silver nanoparticles and tamoxifen in breast cancer cells. J Biochem Mol Toxicol. 2024;38(10):e23823.","journal-title":"J Biochem Mol Toxicol"},{"key":"4056_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s10528-024-10907-1","author":"N Bashari","year":"2024","unstructured":"Bashari N, Naghizadeh M, Chegini MK, Sadeghi ES, Zamani A, Mahdevar M. Therapeutic potential of PLK1, KIF4A, CDCA5, UBE2C, CDT1, SKA3, AURKB, and PTTG1 genes in Triple-Negative breast cancer: correlating their expression with sensitivity to GSK 461364 and IKK 16 drugs. Biochem Genet. 2024. https:\/\/doi.org\/10.1007\/s10528-024-10907-1.","journal-title":"Biochem Genet"},{"issue":"1","key":"4056_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-015-0778-7","volume":"16","author":"P Li","year":"2015","unstructured":"Li P, Piao Y, Shon HS, Ryu KH. Comparing the normalization methods for the differential analysis of Illumina high-throughput RNA-Seq data. BMC Bioinformatics. 2015;16(1):347.","journal-title":"BMC Bioinformatics"},{"issue":"2","key":"4056_CR30","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s12668-024-01348-6","volume":"14","author":"H Tajmehri","year":"2024","unstructured":"Tajmehri H, Mousavi FS, heydarnezhad M, Golrokh FJ, Nezami PV, Khanpour P, et al. Evaluation of the cytotoxic effect of cobalt oxide nanoparticles functionalized by glucose and conjugated with lapatinib (Co3O4@ Glu-Lapatinib) on a lung cancer cell line and evaluation of the expression of CASP8, mTOR1, and MAPK1 genes. BioNanoScience. 2024;14(2):999\u20131010.","journal-title":"BioNanoScience"},{"issue":"8","key":"4056_CR31","doi-asserted-by":"publisher","first-page":"9135","DOI":"10.18632\/oncotarget.7035","volume":"7","author":"C-Y Liu","year":"2016","unstructured":"Liu C-Y, Hu M-H, Hsu C-J, Huang C-T, Wang D-S, Tsai W-C, et al. Lapatinib inhibits CIP2A\/PP2A\/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. Oncotarget. 2016;7(8):9135.","journal-title":"Oncotarget"},{"issue":"2","key":"4056_CR32","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1158\/1535-7163.MCT-06-0423","volume":"6","author":"R Nahta","year":"2007","unstructured":"Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther. 2007;6(2):667\u201374.","journal-title":"Mol Cancer Ther"},{"key":"4056_CR33","doi-asserted-by":"crossref","unstructured":"Nahta R, Yuan LXH, Zhang B, Kobayashi R, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor-I signaling. Clin Cancer Res. 2007;13(16):4909\u20134917.","DOI":"10.1158\/1535-7163.MCT-06-0423"},{"key":"4056_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-10-188","volume":"10","author":"R Diaz","year":"2010","unstructured":"Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I, Redrado M, et al. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer. 2010;10:1\u201310.","journal-title":"BMC Cancer"},{"key":"4056_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/1533034617749418","volume":"17","author":"M Guan","year":"2018","unstructured":"Guan M, Tong Y, Guan M, Liu X, Wang M, Niu R, et al. Lapatinib inhibits breast cancer cell proliferation by influencing PKM2 expression. Technol Cancer Res Treat. 2018;17:1533034617749418.","journal-title":"Technol Cancer Res Treat"},{"issue":"9","key":"4056_CR36","first-page":"1725","volume":"8","author":"MR Guda","year":"2018","unstructured":"Guda MR, Asuthkar S, Labak CM, Tsung AJ, Alexandrov I, Mackenzie MJ, et al. Targeting PDK4 inhibits breast cancer metabolism. Am J Cancer Res. 2018;8(9):1725.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"4056_CR37","first-page":"73","volume":"45","author":"S Shujuan","year":"2018","unstructured":"Shujuan S, Meisong Z, Yingyan H, Juanzi W, Peng W, Jia L. PDK4 mRNA expression in breast cancer and its relationship with prognosis. Cancer Research on Prevention and Treatment. 2018;45(2):73\u20136.","journal-title":"Cancer Research on Prevention and Treatment"},{"key":"4056_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40064-015-1444-2","volume":"4","author":"W Walter","year":"2015","unstructured":"Walter W, Thomalla J, Bruhn J, Fagan DH, Zehowski C, Yee D, et al. Altered regulation of PDK4 expression promotes antiestrogen resistance in human breast cancer cells. Springerplus. 2015;4:1\u201313.","journal-title":"Springerplus"},{"key":"4056_CR39","doi-asserted-by":"publisher","DOI":"10.1177\/10732748241305835","volume":"31","author":"H-Q Duong","year":"2024","unstructured":"Duong H-Q, Hoang M-C, Nguyen T-H, Nguyen P-T, Le V-T, Dao T-N, et al. Aldehyde dehydrogenase-1A1 (ALDH1A1): the novel regulator of chemoresistance in pancreatic cancer cells. Cancer Control. 2024;31:10732748241305835.","journal-title":"Cancer Control"},{"key":"4056_CR40","doi-asserted-by":"crossref","unstructured":"Liu Y, Lv D-l, Duan J-j, Xu S-l, Zhang J-f, Yang X-j, et al. ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysis. BMC cancer. 2014;14(1):444.","DOI":"10.1186\/1471-2407-14-444"},{"issue":"5","key":"4056_CR41","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2025.14959","volume":"29","author":"L Varisli","year":"2025","unstructured":"Varisli L, Zoumpourlis P, Spandidos DA, Zoumpourlis V, Vlahopoulos S. ALDH1A1 in breast cancer: a prospective target to overcome therapy resistance. Oncol Lett. 2025;29(5):213.","journal-title":"Oncol Lett"},{"issue":"10","key":"4056_CR42","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.3390\/ijms18102039","volume":"18","author":"AK Croker","year":"2017","unstructured":"Croker AK, Rodriguez-Torres M, Xia Y, Pardhan S, Leong HS, Lewis JD, et al. Differential functional roles of ALDH1A1 and ALDH1A3 in mediating metastatic behavior and therapy resistance of human breast cancer cells. Int J Mol Sci. 2017;18(10):2039.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4056_CR43","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/his.14129","volume":"77","author":"M Althobiti","year":"2020","unstructured":"Althobiti M, El Ansari R, Aleskandarany M, Joseph C, Toss MS, Green AR, et al. The prognostic significance of ALDH1A1 expression in early invasive breast cancer. Histopathology. 2020;77(3):437\u201348.","journal-title":"Histopathology"},{"issue":"23","key":"4056_CR44","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.1158\/0008-5472.CAN-21-1337","volume":"81","author":"C Liu","year":"2021","unstructured":"Liu C, Qiang J, Deng Q, Xia J, Deng L, Zhou L, et al. ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression. Cancer Res. 2021;81(23):5919\u201334.","journal-title":"Cancer Res"},{"key":"4056_CR45","doi-asserted-by":"publisher","DOI":"10.1242\/dev.201786","author":"SM Kanai","year":"2023","unstructured":"Kanai SM, Clouthier DE. Endothelin signaling in development. Development. 2023. https:\/\/doi.org\/10.1242\/dev.201786.","journal-title":"Development"},{"issue":"1","key":"4056_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-90159-0","volume":"15","author":"H Xiao","year":"2025","unstructured":"Xiao H, Ni J, Yu Q. Identification of ECE2 signaling in promoting non-small lung cancer progression through ET1\/YAP1\/MAGEA3 axis. Sci Rep. 2025;15(1):5626.","journal-title":"Sci Rep"},{"key":"4056_CR47","doi-asserted-by":"crossref","unstructured":"Zhang YH, Zeng J, Liu XS, Gao Y, Kui XY, Liu XY, et al. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of various cancers including ovarian serous cystadenocarcinoma. Front Endocrinol. 2022;13:1013238.","DOI":"10.3389\/fendo.2022.1013238"},{"issue":"1","key":"4056_CR48","doi-asserted-by":"publisher","first-page":"003685042413123","DOI":"10.1177\/00368504241312305","volume":"108","author":"W Ding","year":"2025","unstructured":"Ding W, Han W, Shi C-T, Yao L-Q, Liang Z-W, Zhou M-H, et al. Roles of the CDCA gene family in breast carcinoma. Sci Prog. 2025;108(1):00368504241312305.","journal-title":"Sci Prog"},{"issue":"4","key":"4056_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2022.8387","volume":"48","author":"H Hu","year":"2022","unstructured":"Hu H, Xiang Y, Zhang X-Y, Deng Y, Wan F-J, Huang Y, et al. CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker. Oncol Rep. 2022;48(4):1\u201311.","journal-title":"Oncol Rep"},{"issue":"9","key":"4056_CR50","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.7150\/jca.35372","volume":"11","author":"G Fu","year":"2020","unstructured":"Fu G, Xu Z, Chen X, Pan H, Wang Y, Jin B. CDCA5 functions as a tumor promoter in bladder cancer by dysregulating mitochondria-mediated apoptosis, cell cycle regulation and PI3k\/AKT\/mTOR pathway activation. J Cancer. 2020;11(9):2408.","journal-title":"J Cancer"},{"issue":"1","key":"4056_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-01982-0","volume":"21","author":"W Yin","year":"2021","unstructured":"Yin W, Zhu H, Tan J, Xin Z, Zhou Q, Cao Y, et al. Identification of collagen genes related to immune infiltration and epithelial-mesenchymal transition in glioma. Cancer Cell Int. 2021;21(1):276.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"4056_CR52","first-page":"1875","volume":"40","author":"J Wang","year":"2018","unstructured":"Wang J, Xia C, Pu M, Dai B, Yang X, Shang R, et al. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma. Oncol Rep. 2018;40(4):1875\u201384.","journal-title":"Oncol Rep"},{"key":"4056_CR53","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ebiom.2019.07.030","volume":"46","author":"J Xu","year":"2019","unstructured":"Xu J, Zhu C, Yu Y, Wu W, Cao J, Li Z, et al. Systematic cancer-testis gene expression analysis identified CDCA5 as a potential therapeutic target in esophageal squamous cell carcinoma. EBioMedicine. 2019;46:54\u201365.","journal-title":"EBioMedicine"},{"issue":"7","key":"4056_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.4113","volume":"42","author":"WY Al-Asiri","year":"2024","unstructured":"Al-Asiri WY, Al-Sheddi ES, Farshori NN, Al-Oqail MM, Al-Massarani SM, Malik T, et al. Cytotoxic and Apoptotic Effects of Green Synthesized Silver Nanoparticles via Reactive Oxygen Species-Mediated Mitochondrial Pathway in Human Breast Cancer Cells. Cell Biochem Funct. 2024;42(7):e4113.","journal-title":"Cell Biochem Funct"},{"issue":"16","key":"4056_CR55","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.2217\/nnm-2021-0098","volume":"16","author":"J-H Quan","year":"2021","unstructured":"Quan J-H, Gao FF, Chu J-Q, Cha G-H, Yuk J-M, Wu W, et al. Silver nanoparticles induce apoptosis via NOX4-derived mitochondrial reactive oxygen species and endoplasmic reticulum stress in colorectal cancer cells. Nanomedicine. 2021;16(16):1357\u201375.","journal-title":"Nanomedicine"},{"key":"4056_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jare.2017.10.008","volume":"9","author":"M Akter","year":"2018","unstructured":"Akter M, Sikder MT, Rahman MM, Ullah AA, Hossain KFB, Banik S, et al. A systematic review on silver nanoparticles-induced cytotoxicity: Physicochemical properties and perspectives. J Adv Res. 2018;9:1\u201316.","journal-title":"J Adv Res"},{"key":"4056_CR57","doi-asserted-by":"crossref","unstructured":"Venturelli L, Nappini S, Bulfoni M, Gianfranceschi G, Dal Zilio S, Coceano G, et al. Glucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cells. Sci Rep. 2016;6(1):21629.","DOI":"10.1038\/srep21629"},{"key":"4056_CR58","doi-asserted-by":"crossref","unstructured":"Ren Z, Zhao J, Li S, Yuan H. Targeting glucose transporter 1 (GLUT1) in cancer: molecular mechanisms and nanomedicine applications. Int J Nanomed. 2025:11859\u201379.","DOI":"10.2147\/IJN.S534976"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04056-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04056-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04056-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:01:24Z","timestamp":1783634484000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04056-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4056"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04056-w","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The presented research was approved by the Biomedical Ethics Committee of the Islamic Azad University of Rasht with the Ethics Code of IR.IAU.SHK.REC.1402.032.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}